<DOC>
	<DOCNO>NCT03077256</DOCNO>
	<brief_summary>This prospective registry design observational study ascertain commercially available Burst Products use foot ankle surgeon perform procedure involve bone grafting , well determine relevant patient outcome .</brief_summary>
	<brief_title>Burst Biologics Foot Ankle Registry</brief_title>
	<detailed_description>Foot ankle surgery require use bone graft common despite recent advancement improve outcomes new motion preservation device ( ankle replacement ) . Autogenous bone remain gold standard complicate donor site morbidity availability sufficient volume graft . Over past two decade surgeon interest alternative bone graft steadily increase . Bone morphogenic protein , synthetic bone graft substitute , various allograft product widely available surgeon . Limitations use allografts past mainly attribute less optimal donor screen process technique remove viable component need aid bone heal process . In recent year , focus scientific advance various allograft process technique allow retention various viable cytokine , growth factor , cell population result enhance osteogenic osteoinductive property . Rigorous donor bone screen meticulous test virtually eliminate risk disease transmission . A unique proprietary cryoprotection processing technique ( ProgenokineÂ® ) allograft tissue develop Smart-Surgical , Inc. complete line allograft product create market Burst Biologics ( dba ) . In addition , rigorous standardize laboratory assay technique statistical analysis provide consistency uniformity biologically active component Burst allograft product . This prospective registry design observational study ascertain commercially available Burst Products use foot ankle surgeon perform procedure involve bone grafting , well determine relevant patient outcome .</detailed_description>
	<criteria>Patient age 18 year old Patient diagnose pathology hindfoot , foot , ankle require surgical intervention . The surgeon determine Burst Biologic product clinically indicated . Patient capable understanding content Informed Consent Form . Patient willing able participate registry protocol include surgeon 's standard followup visit clinical evaluation . Patient agree participate registry provide consent per applicable local law declaration Helsinki . The following relative contraindication use Burst Products , however investigator surgeon solely responsible determination patient eligibility surgery : Severe vascular neurological disease Uncontrolled diabetes Severe degenerative disease ( degenerative disc disease ) Hypercalcemia , abnormal calcium metabolism Existing acute chronic infection , especially site operation Inflammatory bone disease osteomyelitis Malignant tumor Patients plan become pregnant .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>Ankle Arthrodesis</keyword>
	<keyword>Cellular Allograft</keyword>
</DOC>